Unlike the case of most gene therapies that are intended to permanently alter their
target cells, however, Oisín's senoablative genetic constructs will not be inserted permanently into the patient's genome: instead, its genetic payload will be expressed temporarily from the
main body of the cell, following which the construct will be passively degraded by normal
cellular metabolism.